Last reviewed · How we verify
dose expansion of SIM0609 in PDAC cohort
dose expansion of SIM0609 in PDAC cohort is a Small molecule drug developed by Jiangsu Simcere Pharmaceutical Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | dose expansion of SIM0609 in PDAC cohort |
|---|---|
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dose expansion of SIM0609 in PDAC cohort CI brief — competitive landscape report
- dose expansion of SIM0609 in PDAC cohort updates RSS · CI watch RSS
- Jiangsu Simcere Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about dose expansion of SIM0609 in PDAC cohort
What is dose expansion of SIM0609 in PDAC cohort?
dose expansion of SIM0609 in PDAC cohort is a Small molecule drug developed by Jiangsu Simcere Pharmaceutical Co., Ltd..
Who makes dose expansion of SIM0609 in PDAC cohort?
dose expansion of SIM0609 in PDAC cohort is developed by Jiangsu Simcere Pharmaceutical Co., Ltd. (see full Jiangsu Simcere Pharmaceutical Co., Ltd. pipeline at /company/jiangsu-simcere-pharmaceutical-co-ltd).
What development phase is dose expansion of SIM0609 in PDAC cohort in?
dose expansion of SIM0609 in PDAC cohort is in Phase 1.